LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 41

Search options

  1. Article ; Online: Combining onabotulinumtoxin A with a CGRP antagonist for chronic migraine prophylaxis: where do we stand?

    Pellesi, Lanfranco

    Frontiers in pain research (Lausanne, Switzerland)

    2023  Volume 4, Page(s) 1292994

    Language English
    Publishing date 2023-10-27
    Publishing country Switzerland
    Document type Journal Article
    ISSN 2673-561X
    ISSN (online) 2673-561X
    DOI 10.3389/fpain.2023.1292994
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Editorial: Novel migraine therapies: consolidating evidence from the real world.

    Pellesi, Lanfranco

    Frontiers in pain research (Lausanne, Switzerland)

    2023  Volume 4, Page(s) 1340268

    Language English
    Publishing date 2023-12-05
    Publishing country Switzerland
    Document type Editorial
    ISSN 2673-561X
    ISSN (online) 2673-561X
    DOI 10.3389/fpain.2023.1340268
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: The human NTG model of migraine in drug discovery and development.

    Pellesi, Lanfranco

    Expert opinion on drug discovery

    2023  Volume 18, Issue 10, Page(s) 1077–1085

    Abstract: Introduction: Various triggers can originate a migraine attack. In healthy volunteers and patients with migraine, the nitroglycerin (NTG) provocation model induces a headache that resembles migraine in pain characteristics and vascular manifestations. ... ...

    Abstract Introduction: Various triggers can originate a migraine attack. In healthy volunteers and patients with migraine, the nitroglycerin (NTG) provocation model induces a headache that resembles migraine in pain characteristics and vascular manifestations. This headache is reversible and treatable in monitored conditions, providing an opportunity to test novel antimigraine medications in early clinical development.
    Areas covered: This perspective covers the main characteristics and applications of the human NTG model of migraine with effective and ineffective antimigraine therapies.
    Expert opinion: The NTG model represents a potential de-risking strategy to test novel hypotheses for antimigraine mechanisms in humans. Considering previous studies conducted with effective and ineffective antimigraine therapies, the sensitivity of the model was 71% while the specificity was 100%. The probability that following an analgesic effect, that compound would truly be efficacious in individuals with migraine was 100%. Following a negative result, the probability that such compound would truly be ineffective in patients with individuals was 33%. A clinical trial testing the analgesic properties of novel compounds after a sublingual and/or intravenous NTG challenge in migraine patients may support a subsequent phase 2 trial for the treatment of migraine.
    MeSH term(s) Humans ; Analgesics/pharmacology ; Drug Discovery ; Headache ; Migraine Disorders/drug therapy ; Nitroglycerin/adverse effects ; Nitroglycerin/pharmacology
    Chemical Substances Analgesics ; Nitroglycerin (G59M7S0WS3)
    Language English
    Publishing date 2023-07-12
    Publishing country England
    Document type Journal Article
    ZDB-ID 2259618-5
    ISSN 1746-045X ; 1746-0441
    ISSN (online) 1746-045X
    ISSN 1746-0441
    DOI 10.1080/17460441.2023.2236545
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6388: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Combining two CGRP inhibitors to treat migraine.

    Pellesi, Lanfranco

    Expert opinion on drug safety

    2022  Volume 21, Issue 9, Page(s) 1135–1136

    MeSH term(s) Calcitonin Gene-Related Peptide ; Calcitonin Gene-Related Peptide Receptor Antagonists/pharmacology ; Humans ; Migraine Disorders/drug therapy
    Chemical Substances Calcitonin Gene-Related Peptide Receptor Antagonists ; Calcitonin Gene-Related Peptide (JHB2QIZ69Z)
    Language English
    Publishing date 2022-10-03
    Publishing country England
    Document type Editorial
    ZDB-ID 2088728-0
    ISSN 1744-764X ; 1474-0338
    ISSN (online) 1744-764X
    ISSN 1474-0338
    DOI 10.1080/14740338.2022.2130890
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6096: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention.

    Pellesi, Lanfranco / Ashina, Messoud / Martelletti, Paolo

    Expert opinion on emerging drugs

    2024  Volume 29, Issue 1, Page(s) 57–64

    Abstract: Introduction: The pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) has emerged as a key mediator of migraine pathogenesis. PACAP-38 and its receptors are predominantly distributed in arteries, sensory and parasympathetic neurons of the ... ...

    Abstract Introduction: The pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) has emerged as a key mediator of migraine pathogenesis. PACAP-38 and its receptors are predominantly distributed in arteries, sensory and parasympathetic neurons of the trigeminovascular system. Phase 2 trials have tested human monoclonal antibodies designed to bind and inhibit PACAP-38 and the pituitary adenylate cyclase-activating polypeptide type I (PAC
    Areas covered: This review focuses on the significance of the PACAP-38 pathway as a target in migraine prevention. English peer-reviewed articles were searched in PubMed, Scopus and ClinicalTrials.gov electronic databases.
    Expert opinion: A PAC
    MeSH term(s) Humans ; Pituitary Adenylate Cyclase-Activating Polypeptide/pharmacology ; Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism ; Migraine Disorders/drug therapy ; Migraine Disorders/prevention & control ; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I ; Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal/pharmacology
    Chemical Substances Pituitary Adenylate Cyclase-Activating Polypeptide ; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I ; Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal
    Language English
    Publishing date 2024-02-12
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2061369-6
    ISSN 1744-7623 ; 1472-8214
    ISSN (online) 1744-7623
    ISSN 1472-8214
    DOI 10.1080/14728214.2024.2317778
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 1925: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Triptan treatment is associated with a higher number of red wine-induced migraine episodes: An exploratory questionnaire-based survey.

    Nedergaard, Laura / Martens, Maria Celine / Christensen, Michala Daniela Bach / Pellesi, Lanfranco

    Pain practice : the official journal of World Institute of Pain

    2024  

    Abstract: Aim: Diet, including foods and beverages, affects migraine. Conversely, the influence of migraine therapies on dietary habits is largely unknown. This study aimed at investigating the effects of triptan intake on foods and drinks consumed by adults with ...

    Abstract Aim: Diet, including foods and beverages, affects migraine. Conversely, the influence of migraine therapies on dietary habits is largely unknown. This study aimed at investigating the effects of triptan intake on foods and drinks consumed by adults with migraine with and/or without aura.
    Methods: An exploratory questionnaire-based survey took place online between November 2022 and June 2023. Participants were recruited through advertisements shared on social media accounts (e.g., Facebook and Instagram) and seasonal newsletters of three Danish patient associations. In addition, posters and flyers in headache and pain centers at Danish hospitals and private neurological, pain, and physiotherapeutic clinics were utilized.
    Results: A total of 314 adults with migraine with and/or without aura completed the survey. Among the respondents, 236 individuals (75.2%) regularly used triptans to treat their migraines. Compared with non-triptan users, individuals using triptans were characterized by significantly more foods and/or drinks triggering migraine (74.2% vs. 56.4%, p = 0.005). Alcoholic beverages and most specifically red wine were overreported as migraine triggers by triptan users (48.3% vs. 21.8%, p < 0.001). In the week preceding the survey, red wine was significantly less consumed by triptan users than non-triptan users (92.4% vs. 76.9%, p < 0.001).
    Conclusions: Patients who regularly consume triptans report red wine most frequently as a migraine trigger. Triptan users are characterized by a lower consumption of red wine than non-triptan users, suggesting that a regular triptan intake may promote an increased sensitivity to red wine-induced migraine.
    Language English
    Publishing date 2024-03-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2151272-3
    ISSN 1533-2500 ; 1530-7085
    ISSN (online) 1533-2500
    ISSN 1530-7085
    DOI 10.1111/papr.13365
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5928: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review.

    Lo Castro, Flavia / Guerzoni, Simona / Pellesi, Lanfranco

    Drug, healthcare and patient safety

    2021  Volume 13, Page(s) 233–240

    Abstract: The treatment of migraine is often complicated by insufficient headache relief, a miscellany of side effects and the risk of developing Medication Overuse Headache (MOH). Novel acute therapies have been recently developed and are now in the early post- ... ...

    Abstract The treatment of migraine is often complicated by insufficient headache relief, a miscellany of side effects and the risk of developing Medication Overuse Headache (MOH). Novel acute therapies have been recently developed and are now in the early post-marketing phase. Lasmiditan is a highly selective serotonin receptor agonist that binds to the 5-HT
    Language English
    Publishing date 2021-11-23
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2520700-3
    ISSN 1179-1365
    ISSN 1179-1365
    DOI 10.2147/DHPS.S304373
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Clinical Evidence of Cannabinoids in Migraine: A Narrative Review.

    Lo Castro, Flavia / Baraldi, Carlo / Pellesi, Lanfranco / Guerzoni, Simona

    Journal of clinical medicine

    2022  Volume 11, Issue 6

    Abstract: The endocannabinoid system (ECS) influences many biological functions, and hence, its pharmacological modulation may be useful for several disorders, such as migraine. Preclinical studies have demonstrated that the ECS is involved in the modulation of ... ...

    Abstract The endocannabinoid system (ECS) influences many biological functions, and hence, its pharmacological modulation may be useful for several disorders, such as migraine. Preclinical studies have demonstrated that the ECS is involved in the modulation of trigeminal excitability. Additionally, clinical data have suggested that an endocannabinoid deficiency is associated with migraine. Given these data, phytocannabinoids, as well as synthetic cannabinoids, have been tried as migraine treatments. In this narrative review, the current clinical evidence of potential ECS involvement in migraine pathogenesis is summarized. Furthermore, studies exploring the clinical effects of phytocannabinoids and synthetic cannabinoids on migraine patients are reviewed.
    Language English
    Publishing date 2022-03-08
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm11061479
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Clinical Evidence of Cannabinoids in Migraine

    Flavia Lo Castro / Carlo Baraldi / Lanfranco Pellesi / Simona Guerzoni

    Journal of Clinical Medicine, Vol 11, Iss 1479, p

    A Narrative Review

    2022  Volume 1479

    Abstract: The endocannabinoid system (ECS) influences many biological functions, and hence, its pharmacological modulation may be useful for several disorders, such as migraine. Preclinical studies have demonstrated that the ECS is involved in the modulation of ... ...

    Abstract The endocannabinoid system (ECS) influences many biological functions, and hence, its pharmacological modulation may be useful for several disorders, such as migraine. Preclinical studies have demonstrated that the ECS is involved in the modulation of trigeminal excitability. Additionally, clinical data have suggested that an endocannabinoid deficiency is associated with migraine. Given these data, phytocannabinoids, as well as synthetic cannabinoids, have been tried as migraine treatments. In this narrative review, the current clinical evidence of potential ECS involvement in migraine pathogenesis is summarized. Furthermore, studies exploring the clinical effects of phytocannabinoids and synthetic cannabinoids on migraine patients are reviewed.
    Keywords Δ9-tetrahydrocannabinol ; cannabidiol ; cannabis ; endocannabinoid system ; headache ; migraine ; Medicine ; R
    Language English
    Publishing date 2022-03-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article: Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study.

    Deligianni, Christina / Pellesi, Lanfranco / Chaudhry, Basit Ali / Haulund Vollesen, Anne Luise / Snoer, Agneta Henriette / Hannibal, Jens / Jensen, Rigmor Højland / Ashina, Messoud

    Frontiers in neurology

    2023  Volume 14, Page(s) 1135246

    Abstract: Background: Pituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) provoked cluster headache attacks in individuals with episodic cluster headache during their active phase and individuals with chronic cluster ... ...

    Abstract Background: Pituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) provoked cluster headache attacks in individuals with episodic cluster headache during their active phase and individuals with chronic cluster headache. In this study, we investigated whether infusions of PACAP and VIP caused alterations in plasma levels of VIP and their potential contribution to induced cluster headache attacks.
    Methods: Participants received either PACAP or VIP infusion for 20 min on 2 separate days with an interval of at least 7 days in between. Blood collection was performed at T
    Results: Blood samples were collected from participants with episodic cluster headache in the active phase (eCHA,
    Conclusion: Cluster headache attacks induced by PACAP38 or VIP infusion are not associated with changes in plasma levels of VIP. Further studies are needed to investigate the role of VIP and the parasympathetic system in cluster headache.
    Clinical trial registration: The parent study is registered at ClinicalTrials.gov (NCT03814226).
    Language English
    Publishing date 2023-04-18
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2564214-5
    ISSN 1664-2295
    ISSN 1664-2295
    DOI 10.3389/fneur.2023.1135246
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top